Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbCellera Biologics Inc (ABCL) vs Invesco DB Commodity Index Tracking Fund (DBC) Price & Performance

AbCellera Biologics IncTrade
Invesco DB Commodity Index Tracking FundTrade

Price performance (Past 24H)

Key statistics

AbCellera Biologics Inc vs Invesco DB Commodity Index Tracking Fund — how do they compare? AbCellera Biologics Inc trades at $9.34 (market cap $2.85B), while Invesco DB Commodity Index Tracking Fund trades at $29.97. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, Invesco DB Commodity Index Tracking Fund nearer its low. Which is the better fit depends on your goals.

ABCLDBC
Market Cap
$2.85B
Sector
HealthCommodities - Metals/Agriculture
52-Week High
$9.34$31.69
52-Week Low
$2.78$21.62
Enterprise Value
$2.45B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbCellera Biologics Inc

ABCL's stock surged 6.13% to $6.93, driven by positive Phase 2 trial results for its menopause drug ABCL635, which showed an 83% reduction in hot flashes. Despite a bullish technical signal and strong analyst consensus (91.67% buy ratings), the company faces fundamental challenges with a net income margin of -248.84% and negative cash flow from operations. Revenue declined from $485M in 2022 to $75M in 2025, though recent news highlights potential from clinical advancements and a collaboration with Vertex.

The outlook is mixed: near-term optimism hinges on drug development success, but high valuation ratios (P/S of 31.63) and persistent losses pose risks. Investors should weigh the 54% upside to the $10.67 price target against cash burn and competitive pressures in biotech.

Invesco DB Commodity Index Tracking Fund

DBC trades at $28.91, up 0.17% on the day, with a bearish technical signal from moving averages and neutral oscillators. Financial ratios are unavailable in the provided data. Recent news highlights commodities ETFs as inflation hedges, with articles discussing portfolio strategies and geopolitical impacts on commodity markets.

The outlook for DBC is clouded by bearish technicals and lack of fundamental data. Commodity market volatility from geopolitical tensions offers potential upside, but investors face risks from unclear financial health and market sentiment shifts. Careful evaluation of upcoming earnings and analyst coverage is essential.

Returns comparison

Trailing returns across standard periods

About AbCellera Biologics Inc

AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.

Read more on ABCL

About Invesco DB Commodity Index Tracking Fund

DBC is a diversified commodity ETF that tracks the DBIQ Optimum Yield Diversified Commodity Index. It invests in futures contracts for 14 heavily traded commodities, including crude oil, gold, and corn, while optimizing for yield and roll costs.

Read more on DBC